Related Experiment Videos
COX-2 and colon cancer
1Laboratory of Biomedical Genetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. taketo@mol.f.u-tokyo.ac.jp
Abstract:
The role of cyclooxygenase-2 (COX-2) in colorectal tumorigenesis in mice was studied by Oshima et al. to determine the effects of COX-2 gene knockouts and a new COX-2 inhibitor. In the study, heterozygous Apcdelta716 knockout mice, a mouse model of human familial adenomatous polyposis (FAP), were either crossed to COX-2 gene knockout mice, or fed chow containing the COX-2-selective inhibitor. Apcdelta716 litter mates were used as positive controls, which developed 652+/-198 (SD) polyps at 10 weeks. Introduction of a COX-2 gene mutation, or feeding with the COX-2-selective inhibitor to the Apcdelta716 knockout mice, reduced the number and size of intestinal polyps dramatically. The results provide direct genetic evidence that COX-2 plays a key role in tumorigenesis, and indicate that COX-2-selective inhibitors can be a new class of therapeutic agents for colorectal polyposis and cancer.
Insights
Cyclooxygenase-2 (COX-2) significantly drives colorectal tumor growth in mice. Inhibiting COX-2 or knocking out its gene dramatically reduced intestinal polyps, suggesting therapeutic potential.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Familial adenomatous polyposis (FAP) is a hereditary condition characterized by numerous intestinal polyps.
- Cyclooxygenase-2 (COX-2) is an enzyme implicated in inflammation and cancer development.
- Understanding COX-2's role in colorectal tumorigenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of COX-2 in colorectal tumorigenesis using a mouse model.
- To evaluate the effects of COX-2 gene knockout on polyp development.
- To assess the efficacy of a COX-2-selective inhibitor in preventing polyp formation.
Main Methods:
- Utilized heterozygous Apcdelta716 knockout mice, a model for human FAP.
- Crossed Apcdelta716 mice with COX-2 gene knockout mice.
- Administered a COX-2-selective inhibitor to Apcdelta716 mice via chow.
- Used Apcdelta716 littermates as positive controls.
Main Results:
- Apcdelta716 mice developed a high number of intestinal polyps (652+/-198 SD at 10 weeks).
- Both COX-2 gene mutation and COX-2 inhibitor treatment significantly reduced polyp number and size.
- Demonstrated a dramatic reduction in intestinal polyps in treated/mutated mice.
Conclusions:
- Provided direct genetic evidence for COX-2's critical role in colorectal tumorigenesis.
- Indicated that COX-2-selective inhibitors represent a promising therapeutic strategy for colorectal polyposis.
- Supported the potential of COX-2 inhibitors as agents for colorectal cancer prevention and treatment.